Does partial surgical tumour removal influence the response to octreotide‐LAR in acromegalic patients previously resistant to the somatostatin analogue?
- 10 May 2007
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 67 (2) , 310-315
Abstract
Summary: Objective To compare the intrapatient response to the same dose of slow‐release octreotide (OCT‐LAR) before and after noncurative surgery in acromegalic patients who did not attain disease control after primary treatment with OCT‐LAR.Design Prospective clinical study.Patients Eleven acromegalic patients (eight men, aged 42·45 ± 11·15 years, 10 macroadenomas) received OCT‐LAR (20 mg, n = 1; 30 mg, n = 10) every 28 days as the primary treatment (1stOCT‐LAR) for 11·3 ± 4·2 months, without IGF‐I normalization. They were subsequently submitted to surgery without cure and were then treated with the same dose of OCT‐LAR for 8·0 ± 6·5 months (2ndOCT‐LAR).Measurements GH and IGF‐I serum concentrations were obtained under basal conditions as well as during treatment. Pituitary tumour volume was assessed by magnetic resonance imaging (MRI) of the sella. IGF‐I was also expressed as a percentage of the upper limit of the normal age‐ and sex‐matched range (%ULNR IGF‐I).Results After 1stOCT‐LAR, there was a decrease in GH levels (P = 0·003) and %ULNR IGF‐I (P = 0·009) compared to baseline (B), but no IGF‐I normalization. Tumour shrinkage was observed in eight of 10 patients with macroadenomas (median 63·7%, range 24·5–75·5%). After surgery, mean levels of GH and %ULNR IGF‐I were lower than those at baseline (P = 0·0004 and P = 0·003, respectively), but not when compared to values during 1stOCT‐LAR (P = 1·000 and P = 0·957, respectively). MRI confirmed surgical tumour removal (median 64%, range 4·9–96·6%) in eight of the 10 patients. Comparing the 2ndOCT‐LAR results with postsurgical results, there were no significant decrease in %ULNR IGF‐I (P = 0·061) and GH levels (P = 0·414). Nine patients (82%) achieved IGF‐I normalization. The degree of surgical tumour reduction did not correlate with IGF‐I normalization (P = 0·794). When comparing the results between 1stOCT‐LAR and 2ndOCT‐LAR, there was a decrease, albeit not statistically significant, in serum GH levels (P = 0·059) and a significant decrease in %ULNR IGF‐I (P = 0·011).Conclusions Using strict criteria (same patient, same drug, same dose) our results strongly suggest that the surgical reduction of tumour mass can improve the outcome of OCT‐LAR treatment in acromegalic patients resistant to primary therapy with SA.Keywords
This publication has 17 references indexed in Scilit:
- Partial Surgical Removal of Growth Hormone-Secreting Pituitary Tumors Enhances the Response to Somatostatin Analogs in AcromegalyThe Journal of Clinical Endocrinology & Metabolism, 2006
- Treatment of acromegaly with octreotide‐LAR: extensive experience in a Brazilian institutionClinical Endocrinology, 2005
- Efficacy of Sandostatin® LAR® (long‐acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapyClinical Endocrinology, 2004
- Long-Term Effects of Depot Long-Acting Somatostatin Analog Octreotide on Hormone Levels and Tumor Mass in AcromegalyThe Journal of Clinical Endocrinology & Metabolism, 2001
- Transsphenoidal Surgery for Acromegaly: Endocrinological Follow-up of 98 PatientsNeurosurgery, 2001
- Criteria for Cure of Acromegaly: A Consensus StatementThe Journal of Clinical Endocrinology & Metabolism, 2000
- Human Somatostatin Receptor Subtypes in Acromegaly: Distinct Patterns of Messenger Ribonucleic Acid Expression and Hormone Suppression Identify Different Tumoral PhenotypesThe Journal of Clinical Endocrinology & Metabolism, 2000
- Somatostatin and Its Receptor FamilyFrontiers in Neuroendocrinology, 1999
- Transsphenoidal Microsurgery for Growth Hormone-Secreting Pituitary Adenomas: Initial Outcome and Long-Term ResultsThe Journal of Clinical Endocrinology & Metabolism, 1998
- Volume of Pituitary MacroadenomasJournal of Computer Assisted Tomography, 1992